The treatment showed notable efficacy in a group of patients who had already undergone extensive prior therapy for the disease, which affects the kidney's waste-filtering tubules. Sumanta Pal, a study investigator and vice chair at City of Hope Comprehensive Cancer Center, highlighted the drug's performance in this difficult-to-treat population. Following these results, Xencor plans to push the candidate into late-stage clinical development.

Chief Executive Bassil Dahiyat stated that the company remains well-capitalized, with a cash runway extending into 2029. This financial stability supports an accelerated pace of research across both oncology and autoimmune disease portfolios. Investors reacted sharply to the news, pushing shares up by nearly 65% for the year to date as of the end of last week.